• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by LENSAR Inc.

    2/14/22 11:02:34 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care
    Get the next $LNSR alert in real time by email
    SC 13G 1 form_sc13g-lensar.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC  20549

    SCHEDULE 13G
    (Rule 13d-102)

    (Amendment No. )

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO
    RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED
    PURSUANT TO RULE 13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934


    LENSAR, Inc.
    (Name of Issuer)
     
    Common Stock, $0.01 par value
    (Title of Class of Securities)
     
    52634L108
    (CUSIP Number)
     
    December 31, 2021
    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [x] Rule 13d-1(b)
    [  ] Rule 13d-1(c)
    [  ] Rule 13d-1(d)




    CUSIP No. 52634L108
     

    1
    NAME OF REPORTING PERSONS

    North Run Capital, LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)  [  ]
    (b)  [  ]
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER

    0
    6
    SHARED VOTING POWER

    949,000*
    7
    SOLE DISPOSITIVE POWER

    0
    8
    SHARED DISPOSITIVE POWER

    949,000**
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    949,000**
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
    [  ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    8.7%**
    12
    TYPE OF REPORTING PERSON*

    IA, PN

    *SEE INSTRUCTIONS BEFORE FILLING OUT
    **SEE ITEM 4.



    CUSIP No. 52634L108
     

    1
    NAME OF REPORTING PERSONS
     
    North Run Advisors, LLC
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)  [  ]
    (b)  [  ]
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER

    0
    6
    SHARED VOTING POWER

    949,000**
    7
    SOLE DISPOSITIVE POWER

    0
    8
    SHARED DISPOSITIVE POWER

    949,000**
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    949,000**
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
    [  ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    8.7%**
    12
    TYPE OF REPORTING PERSON*

    HC, OO

    *SEE INSTRUCTIONS BEFORE FILLING OUT
    **SEE ITEM 4.


    CUSIP No. 52634L108
     

    1
    NAME OF REPORTING PERSONS
     
    Todd B. Hammer
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)  [  ]
    (b)  [  ]
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER

    0
    6
    SHARED VOTING POWER

    949,000**
    7
    SOLE DISPOSITIVE POWER

    0
    8
    SHARED DISPOSITIVE POWER

    949,000**
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    949,000**
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
    [  ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    8.7%**
    12
    TYPE OF REPORTING PERSON*

    HC, IN

    *SEE INSTRUCTIONS BEFORE FILLING OUT
    **SEE ITEM 4.


    CUSIP No. 52634L108
     

    1
    NAME OF REPORTING PERSONS
     
    Thomas B. Ellis
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)  [  ]
    (b)  [  ]
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER

    0
    6
    SHARED VOTING POWER

    949,000**
    7
    SOLE DISPOSITIVE POWER

    0
    8
    SHARED DISPOSITIVE POWER

    949,000**
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    949,000**
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
    [  ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    8.7%**
    12
    TYPE OF REPORTING PERSON*

    HC, IN

    *SEE INSTRUCTIONS BEFORE FILLING OUT
    **SEE ITEM 4.

    SCHEDULE 13G

    This Schedule 13G (this “Schedule 13G”) is being filed on behalf of North Run Capital, LP, a Delaware limited partnership (the “Investment Manager”), North Run Advisors, LLC, a Delaware limited liability company (“North Run”), Todd B. Hammer and Thomas B. Ellis (collectively, the “Reporting Persons”).  Todd B. Hammer and Thomas B. Ellis are the principals and sole members of North Run.  North Run is the general partner of the Investment Manager.  The Investment Manager is the investment manager of certain private pooled investment vehicles (collectively, the “Funds”).  This Schedule 13G relates to shares of Common Stock, $0.01 par value (the “Common Stock”), of LENSAR, Inc., a Delaware corporation (the “Issuer”), held by the Funds.
    Item 1(a)            Name of Issuer.
    LENSAR, Inc.

    Item 1(b)
    Address of Issuer’s Principal Executive Offices.
    2800 Discovery Drive
    Orlando, Florida 32826

    Item 2(a)            Name of Person Filing.

    (1) North Run Capital, LP
    (2) North Run Advisors, LLC
    (3) Todd B. Hammer
    (4) Thomas B. Ellis

    Item 2(b)            Address of Principal Business Office, or, if none, Residence.

    For all Filers:
    62 Walnut Street
    Wellesley, MA 02481

    Item 2(c)            Citizenship or Place of Organization.

    (1) North Run Capital, LP is a Delaware limited partnership.
    (2) North Run Advisors, LLC is a Delaware limited liability company.
    (3) Todd B. Hammer is a U.S. citizen.
    (4) Thomas B. Ellis is a U.S. citizen.

    Item 2(d)            Title of Class of Securities.

    Common Stock, $0.01 par value.

    Item 2(e)            CUSIP Number.

    52634L108


    Item 3                  Reporting Person.

    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:


    (a)  [   ]
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

    (b)  [   ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

    (c)     [   ]
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

    (d)     [   ]
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

    (e)     [X]
    An investment advisor in accordance with §240.13d-1(b)(1)(ii)(E).

    (f)      [   ]
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

    (g)     [X]
    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).

    (h)     [   ]
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

    (i)      [   ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

    (j)      [   ]
    Group, in accordance with §240.13d-1(b)(1)(ii)(J).
    Item 4                 Ownership.


    (a)
    The Investment Manager, North Run, Todd B. Hammer and Thomas B. Ellis may be deemed the beneficial owners of 949,000 shares of Common Stock.

    (b)
    The Investment Manager, North Run, Todd B. Hammer and Thomas B. Ellis may be deemed the beneficial owners of 8.7% of the outstanding shares of Common Stock.  This percentage was determined by dividing 949,000 by 10,956,688, which is the number of shares of Common Stock outstanding as of October 31, 2021, according to the Issuer’s Form 10-Q filed on November 8, 2021 with the Securities and Exchange Commission.

    (c)
    The Investment Manager, Todd B. Hammer and Thomas B. Ellis have the shared power to vote and dispose of the 949,000 shares of Common Stock beneficially owned.


    Item 5                  Ownership of Five Percent or Less of a Class.

    Inapplicable

    Item 6                 Ownership of More Than Five Percent on Behalf of Another Person.

    Inapplicable.

    Item 7
    Identification and Classification of the Subsidiary which Acquired the Security Being Reported On by the Parent Holding Company.

    Inapplicable

    Item 8                 Identification and Classification of Members of the Group.

    Inapplicable

    Item 9                  Notice of Dissolution of Group.

    Inapplicable

    Item 10
    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Exhibits
    Exhibit 24-1

    Power of Attorney of Thomas B. Ellis, dated February 15, 2018.

    Exhibit 24-2

    Power of Attorney of Todd B. Hammer, dated February 15, 2018.


    Exhibit 99-1

    Joint Filing Agreement, dated February 14, 2022, between North Run, the Investment Manager, Todd B. Hammer and Thomas B. Ellis.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2022
    NORTH RUN CAPITAL, LP

    By:     North Run Advisors, LLC
    its general partner

    By:          /s/ Thomas B. Ellis*
    Name:  Thomas B. Ellis
    Title:  Member
    and

    By:          /s/ Todd B. Hammer*
    Name:  Todd B. Hammer
    Title:  Member

    NORTH RUN ADVISORS, LLC


    By:              /s/ Thomas B. Ellis*
    Name:  Thomas B. Ellis
    Title:  Member

    and


    By:              /s/ Todd B. Hammer*Name:  Todd B. Hammer
    Name: Todd B. Hammer
    Title:  Member


    /s/ Thomas B. Ellis*
    Thomas B. Ellis



    /s/ Todd B. Hammer*
    Todd B. Hammer
    * By   /s/ MICHAEL FISHER
    Michael Fisher, Attorney-in-Fact
             Pursuant to Powers of Attorney filed as exhibits hereto


    EXHIBIT 24-1

    POWER OF ATTORNEY

    I hereby constitute and appoint Michael Fisher, as my true and lawful attorney-in-fact to:

    (1)
    execute for and on my behalf, in my capacity as a member of North Run Advisors, LLC and in my individual capacity, statements of beneficial ownership required to be filed with the Securities and Exchange Commission on Schedule 13G, together with any amendments thereto and all joint filing agreements filed therewith, by North Run Capital, LP, North Run GP, LP, North Run Advisors, LLC, and me, individually, pursuant to Section 13(d) of the Securities Exchange Act of 1934 and the rules promulgated thereunder;

    (2)
    do and perform any and all acts for and on my behalf that may be necessary or desirable to complete and execute and timely file any such Schedule 13G, and any amendments thereto and other forms or agreements associated therewith, with the Securities and Exchange Commission and any stock exchange or similar authority; and

    (3)
    take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be to my benefit, in my best interest, or that I am legally required to do, it being understood that the documents executed by such attorney-in-fact on my behalf pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.
    I hereby grant to such attorney-in-fact full power and authority to do and perform any and every act requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as I might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.
    This Power of Attorney shall remain in full force and effect until the persons identified in clause (1) above are no longer required to file statements of beneficial ownership on Schedule 13G, unless I earlier revoke it in a signed writing delivered to the attorney-in-fact.
    IN WITNESS WHEREOF, I have caused this Power of Attorney to be executed as of this 15th    day of February 2018.
    /s/ THOMAS B. ELLIS
    Signature


    Thomas B. Ellis
    Name (printed)


    EXHIBIT 24-2

    POWER OF ATTORNEY

    I hereby constitute and appoint Michael Fisher, as my true and lawful attorney-in-fact to:

    (1)
    execute for and on my behalf, in my capacity as a member of North Run Advisors, LLC and in my individual capacity, statements of beneficial ownership required to be filed with the Securities and Exchange Commission on Schedule 13G, together with any amendments thereto and all joint filing agreements filed therewith, by North Run Capital, LP, North Run GP, LP, North Run Advisors, LLC, and me, individually, pursuant to Section 13(d) of the Securities Exchange Act of 1934 and the rules promulgated thereunder;

    (2)
    do and perform any and all acts for and on my behalf that may be necessary or desirable to complete and execute and timely file any such Schedule 13G, and any amendments thereto and other forms or agreements associated therewith, with the Securities and Exchange Commission and any stock exchange or similar authority; and

    (3)
    take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be to my benefit, in my best interest, or that I am legally required to do, it being understood that the documents executed by such attorney-in-fact on my behalf pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.
    I hereby grant to such attorney-in-fact full power and authority to do and perform any and every act requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as I might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.
    This Power of Attorney shall remain in full force and effect until the persons identified in clause (1) above are no longer required to file statements of beneficial ownership on Schedule 13G, unless I earlier revoke it in a signed writing delivered to the attorney-in-fact.

    IN WITNESS WHEREOF, I have caused this Power of Attorney to be executed as of this 15th    day of February 2018.
    /s/ TODD B. HAMMER
    Signature


    Todd B. Hammer
    Name (printed)



    EXHIBIT 99-1

    JOINT FILING AGREEMENT

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.01 par value, of LENSAR, Inc., and further agree that this Joint Filing Agreement shall be included as an Exhibit to such joint filings.

    The undersigned further agree that each party hereto is responsible for the timely filing of such Statement on Schedule 13G and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate.

    This Joint Filing Agreement may be signed in counterparts with the same effect as if the signature on each counterpart were upon the same instrument.


    [Signature Page Follows]

    IN WITNESS WHEREOF, the undersigned have executed this Agreement as of February 14, 2022.

    Date: February 14, 2022
    NORTH RUN CAPITAL, LP

    By:     North Run Advisors, LLC
    its general partner

    By:          /s/ Thomas B. Ellis*
    Name:  Thomas B. Ellis
    Title:  Member
    and

    By:          /s/ Todd B. Hammer*
    Name:  Todd B. Hammer
    Title:  Member

    NORTH RUN ADVISORS, LLC


    By:              /s/ Thomas B. Ellis*
    Name:  Thomas B. Ellis
    Title:  Member

    and


    By:              /s/ Todd B. Hammer*Name:  Todd B. Hammer
    Name: Todd B. Hammer
    Title:  Member


    /s/ Thomas B. Ellis*
    Thomas B. Ellis



    /s/ Todd B. Hammer*
    Todd B. Hammer
    * By   /s/ MICHAEL FISHER
    Michael Fisher, Attorney-in-Fact
             Pursuant to Powers of Attorney filed as exhibits hereto


    Get the next $LNSR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LNSR

    DatePrice TargetRatingAnalyst
    11/22/2021$15.00Buy
    BTIG
    More analyst ratings

    $LNSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Staab Thomas R Ii covered exercise/tax liability with 1,826 shares, decreasing direct ownership by 1% to 171,535 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    1/13/26 4:30:07 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Curtis Nicholas T disposed of 0 shares (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    1/13/26 4:30:11 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Connaughton Alan B. covered exercise/tax liability with 2,262 shares, decreasing direct ownership by 0.63% to 359,461 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    1/13/26 4:30:06 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    ORLANDO, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hired non-executive employees an aggregate of 660 restricted stock units ("RSUs"). The RSUs were granted as of September 2, 2025, as inducement for each such employee commencing employment with the Company. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in four substantially equal installments on each anniversary of the grant date, subject to the

    9/2/25 4:01:44 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors

      ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria

    8/19/25 8:00:13 AM ET
    $GERN
    $GMAB
    $LNSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    LENSAR Reports Second Quarter 2025 Results and Provides Business Update

    18 ALLY Robotic Cataract Laser Systems™ ("ALLY Systems") placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025 ALLY installed base grew 107% and total installed base grew 23% over 2Q 2024 Worldwide procedure volumes increased 23% over 2Q 2024 ORLANDO, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2025 and provided an update on key operational initiatives. "Our second quarter results reflect the continued, strong

    8/7/25 7:00:16 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    SEC Filings

    View All

    LENSAR Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - LENSAR, Inc. (0001320350) (Filer)

    12/19/25 4:01:27 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by LENSAR Inc.

    SCHEDULE 13G - LENSAR, Inc. (0001320350) (Subject)

    11/13/25 12:03:17 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by LENSAR Inc.

    10-Q - LENSAR, Inc. (0001320350) (Filer)

    11/6/25 4:01:02 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Winer Gary M bought $3,082 worth of shares (685 units at $4.50), increasing direct ownership by 0.85% to 80,840 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    9/6/24 9:00:13 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Director Winer Gary M bought $10,373 worth of shares (2,302 units at $4.51), increasing direct ownership by 3% to 80,155 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    8/29/24 6:05:46 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Director Winer Gary M bought $2,185 worth of shares (502 units at $4.35), increasing direct ownership by 0.65% to 77,853 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    8/23/24 6:52:16 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG initiated coverage on LENSAR with a new price target

    BTIG initiated coverage of LENSAR with a rating of Buy and set a new price target of $15.00

    11/22/21 6:09:40 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SVB Leerink initiated coverage on LENSAR with a new price target

    SVB Leerink initiated coverage of LENSAR with a rating of Outperform and set a new price target of $20.00

    3/2/21 8:10:50 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SVB Leerink initiated coverage on LENSAR with a new price target

    SVB Leerink initiated coverage of LENSAR with a rating of Outperform and set a new price target of $20.00

    2/24/21 6:12:20 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Financials

    Live finance-specific insights

    View All

    LENSAR Reports Second Quarter 2025 Results and Provides Business Update

    18 ALLY Robotic Cataract Laser Systems™ ("ALLY Systems") placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025 ALLY installed base grew 107% and total installed base grew 23% over 2Q 2024 Worldwide procedure volumes increased 23% over 2Q 2024 ORLANDO, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2025 and provided an update on key operational initiatives. "Our second quarter results reflect the continued, strong

    8/7/25 7:00:16 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR Reports First Quarter 2025 Results and Provides Business Update

             14 ALLY Robotic Laser Cataract Systems™ ("ALLY Systems") placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first quarter 2024 and 22% Recurring revenue growth in the trailing twelve months Worldwide procedure volumes increased 33% over the first quarter of 2024 ORLANDO, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2025 and provided an update on key operational initiatives. "W

    5/8/25 7:00:42 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

    31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company's total installed systems increased to approximately 385 as of December 31, 2024, representing a 26% increase over 2023 Fourth quarter 2024 revenue increased 38% over fourth quarter 2023; Full-year revenue increased 27% over 2023 Recurring revenue exceeds $40 million for the full year; increased 23% over 2023 ORLANDO, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financia

    2/27/25 7:00:11 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by LENSAR Inc.

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    11/14/24 4:05:15 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    2/14/24 4:05:39 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    2/13/24 4:30:02 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Leadership Updates

    Live Leadership Updates

    View All

    SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors

      ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria

    8/19/25 8:00:13 AM ET
    $GERN
    $GMAB
    $LNSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments